Patent shenanigans force stronger response from US authorities

18 September 2023
congress_washington_politics_big

Following scrutiny from Democratic senators in Congress, the US Federal Trade Commission has issued a  policy statement on the proper listing of pharmaceutical patents.

The FTC argues that some drugmakers have failed to properly describe the reference drug or methods for their use, potentially stymying generics drugmakers who wish to develop off-patent versions once the defined period of exclusivity has come to an end.

Problems with the way patents are registered, a process that focuses on the comprehensive “Orange Book” of enforceable US patents for medicines, have been recognized for years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics